Can iron treatments aggravate epistaxis in some patients with hereditary hemorrhagic telangiectasia? by Shovlin, CL et al.
The Laryngoscope
VC 2016 The Authors. The Laryngoscope published by Wiley Periodicals, Inc. on behalf of American Laryngological,
Rhinological and Otological Society Inc, “The Triological Society” and American Laryngological Association (ALA).
Can Iron Treatments Aggravate Epistaxis in Some Patients
With Hereditary Hemorrhagic Telangiectasia?
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Objectives/Hypothesis: To examine whether there is a rationale for iron treatments precipitating nosebleeds (epistaxis)
in a subgroup of patients with hereditary hemorrhagic telangiectasia (HHT).
Study Design: Survey evaluation of HHT patients, and a randomized control trial in healthy volunteers.
Methods: Nosebleed severity in response to iron treatments and standard investigations were evaluated by unbiased
surveys in patients with HHT. Serial blood samples from a randomized controlled trial of 18 healthy volunteers were used to
examine responses to a single iron tablet (ferrous sulfate, 200 mg).
Results: Iron tablet users were more likely to have daily nosebleeds than non–iron-users as adults, but there was no
difference in the proportions reporting childhood or trauma-induced nosebleeds. Although iron and blood transfusions were
commonly reported to improve nosebleeds, 35 of 732 (4.8%) iron tablet users, in addition to 17 of 261 (6.5%) iron infusion
users, reported that their nosebleeds were exacerbated by the respective treatments. These rates were significantly higher
than those reported for control investigations. Serum iron rose sharply in four of the volunteers ingesting ferrous sulfate (by
19.3–33.1 lmol/L in 2 hours), but not in 12 dietary controls (2-hour iron increment ranged from 22.2 to 15.0 lmol/L).
High iron absorbers demonstrated greater increments in serum ferritin at 48 hours, but transient rises in circulating endothe-
lial cells, an accepted marker of endothelial damage.
Conclusions: Iron supplementation is essential to treat or prevent iron deficiency, particularly in patients with patholog-
ical hemorrhagic iron losses. However, in a small subgroup of individuals, rapid changes in serum iron may provoke endothe-
lial changes and hemorrhage.
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INTRODUCTION
Hereditary hemorrhagic telangiectasia (HHT) poses
a substantial burden on otorhinolaryngological practice.
Inherited as an autosomal dominant trait, HHT is
caused by gene defects, most commonly in ENG,
ACVRL1, or SMAD4, and leads to the development of
nasal and gastrointestinal telangiectasia, in addition to
visceral arteriovenous malformations (AVMs).1,2 Recur-
rent epistaxis (nosebleeds) is the hallmark of HHT1–4,
and results from fragile nasal telangiectasia, which are
often lined by a single endothelial layer with no smooth
muscles cells or pericytes, despite acting as conduits for
blood at arterial pressure5 (see Supporting Fig. 1 in the
online version of this article). Nosebleeds often occur
daily, and can be associated with acute hemodynamic
disturbances1,3,4,6,7 and reduced quality of life.8–12 Treat-
ments include surgically based therapies such as cauter-
ization, laser photocoagulation,13 septal dermoplasty,14
and Young’s procedure,15 and medical therapies such as
antioestrogens,16 tranexamic acid,17,18 and bevacizumab
This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original
work is properly cited and is not used for commercial purposes.
Additional supporting information can be found in the online
version of this article.
From Cardiovascular Sciences, National Heart and Lung Institute,
Imperial College London (C.L.S., D.P., C.S., F.N.A., I.A.); Respiratory Medi-
cine, Imperial College Healthcare National Health Service Trust (C.L.S.,
C.G.); Clinical Chemistry, Imperial College Healthcare National Health
Service Trust (M.B.); Department of Surgery and Cancer, Imperial Col-
lege London (R.D.); and Imperial College London School of Medicine
(F.N.A., I.A.), London, United Kingdom.
Editor’s Note: This Manuscript was accepted for publication
February 10, 2016.
Institution where the work was done: Imperial College London,
London, United Kingdom and Hammersmith Hospital, Imperial College
Healthcare National Health Service Trust).
This study received support from the Averil Macdonald Memorial
Trust; the National Institute for Health Research (National Institute for
Health Research [NIHR] North West London Comprehensive Local
Research Network; NIHR Academic Foundation Year Program [C.G.];
NIHR Imperial College Biomedical Research Centre) and the National
Heart and Lung Institute’s BSc Project Funds (to C.L.S. for F.N.A. and
I.A.). The study sponsors played no part in study design; in the collection,
analysis, and interpretation of data; in the writing of the report; or in
the decision to submit the paper for publication. This article includes
independent research carried out at the NIHR/Wellcome Trust Imperial
Clinical Research Facility. The views expressed are those of the authors
and not necessarily those of funders, the National Health Service, the
NIHR, or the Department of Health.
The authors have no other funding, financial relationships, or con-
flicts of interest to disclose.
Send correspondence to Claire L. Shovlin, PhD, FRCP, Reader in
Clinical and Molecular Medicine, NHLI Cardiovascular Sciences,
Imperial Centre for Translational and Experimental Medicine, Imperial
College London, Hammersmith Campus, Du Cane Road, London W12
0NN, United Kingdom. E-mail: c.shovlin@imperial.ac.uk
DOI: 10.1002/lary.25959
Laryngoscope 00: Month 2016 Shovlin et al.: HHT Epistaxis and Iron Treatments:
1
(Avastin).19,20 Therapeutics are generally graded accord-
ing to the severity of epistaxis,21 and many patients
require more than one modality. Further treatment
modalities are currently under evaluation in clinical
trials.
The epistaxis that can be so difficult to manage in
clinical practice also causes additional problems. HHT
patients are commonly iron deficient and/or anemic
because replacing iron lost through recurrent hemor-
rhage demands very high iron intakes, and it is difficult
to meet the hemorrhage-adjusted iron requirement by
dietary intake alone.22 The diverse detrimental conse-
quences of iron deficiency23–26 include anemia and trans-
fusional requirements that occur because iron deficiency
restricts erythropoeisis,27 leading to low hemoglobin,28
and reduced arterial oxygen content.29,30 The develop-
ment of iron deficiency predicts development of high out-
put cardiac failure for HHT patients with severe hepatic
AVMs.31 Additionally, low serum iron is associated with
venous thromboemboli,32 paradoxical embolic stroke
through pulmonary AVMs,33 exuberant platelet aggrega-
tion to 5HT,33,34 and elevated coagulation factor VIII.32
Treatment of iron deficiency and anemia for people
with HHT is essential to prevent these complications.35
In the clinic, however, we were surprised by a small
number of HHT patients who spontaneously volunteered
that they could not use iron tablets or infusions to treat
their iron deficiency because the iron treatments precipi-
tated nosebleeds within hours. This prompted us to
examine whether endothelial cells were modified by iron
concentrations similar to those present in the blood-
stream after iron tablets36–40 or infusions.41,42 Previous
studies demonstrated toxicity at much higher iron con-
centrations, relevant to iron overload disorders or exper-
imental endothelial models.43,44 Our recent work
demonstrates that the more clinically relevant concen-
tration of 10 lM iron generates rapid molecular and cel-
lular changes in primary human endothelial cells,
compatible with activation of DNA damage response
pathways.45
The goal of the current study was to explore whether
such processes might be relevant to human recipients of
iron tablets, particularly patients with HHT.
MATERIALS AND METHODS
HHT Surveys
The primary aims of the Imperial 2012 HHT survey were
to capture acute responses to iron treatments, and to assess dif-
ferences between patients using or not using iron, although the
survey addressed multiple aspects of HHT, with a nonspecific
participant information sheet that did not specify precise study
foci.22,46–48 Relevant survey extracts are presented in Support-
ing Figure 2 in the online version of this article. All respond-
ents were asked about aspects of the HHT phenotype including
the use of iron tablets, and blood transfusions, before they were
separately asked about intravenous iron. Respondents who
stated they had HHT were directed to nonbiased follow-on ques-
tions regarding nosebleeds and iron tablets, infusions, and
transfusions. For each treatment, tick box response options
were: 1) “I do not get nosebleeds,” 2) “I never noticed any differ-
ence in my nosebleeds,” 3) “I think my nosebleeds were better,”
and 4) “I think my nosebleeds were worse.” The survey closed
in April 2013. Following interim assignment of HHT pheno-
types and data analyses, all data were downloaded from Sur-
veyMonkey in December 2015 for the purposes of the current
report.
To provide a control group of nosebleed responses to non-
invasive investigations, similar questions were incorporated in
a further survey,49,50 which asked whether the participant had
completed the 2012 survey. Relevant extracts are presented in
Supporting Figure 3 in the online version of this article. The
second study remained open until April 2015, when 706
patients had completed the survey. Data were downloaded from
SurveyMonkey in August 2015. The 460 responses from people
who had also completed the 2012 survey were analyzed for the
purposes of this study.
Iron Treatment Trial in Healthy Volunteers
Eighteen healthy volunteers (see Supporting Table I in the
online version of this article) were randomly assigned to receive
a 200-mg ferrous sulfate tablet containing 65 mg elemental
iron, a dietary supplement (10 mL molasses containing 2 mg
iron), or no agent on each of 2 consecutive days. The eligibility
criteria were males or females aged 18 to 80 years, who were
not receiving iron supplements, had no needle phobias, and
were able to provide informed consent (see Supporting Figs. 4
and 5 in the online version of this article).51 The trial recruited
February to April 2012, and was conducted at the National
Institute for Health Research/Wellcome Trust Imperial Clinical
Research Facility, Hammersmith Hospital, London, United
Kingdom. Study and sampling completion rates were 100%.
The primary outcome was the absolute serum iron at
serial time points, to compare iron absorption after iron tablet
or dietary supplements to diurnal variation. Additional study
objectives were to obtain research samples to examine parame-
ters of vascular injury, to be categorized by iron absorption sta-
tus if feasible. To prevent any inadvertent study unblinding, 1)
during the study, only C.G. was aware of randomization codes
(generated by Urbaniak/Plous randomization); and 2) biochemi-
cal analyses by M.B. were not performed until 6 months after
circulating endothelial cell (cEC) analyses had been completed
by C.L.S., D.P., and C.S. Serum iron, transferrin saturation index
(TfSI), and ferritin were then measured on Ci1600 Architect
Analyzers (Abbott Diagnostics, Sligo, Ireland), and M.B. catego-
rized the 18 participants as absorbers or nonabsorbers, based
on serial changes, and blinded to experimental groups and
outcomes.
On the day of sample collection, blinded to treatment
group, hematologic variables, including total and differential
leucocyte counts, were measured as part of a complete blood
count, on XE Series Analyzers (Sysmex, Milton Keynes, UK). At
all six time points, plasma and serum samples were stored, and
blood monocytes were harvested to provide a source of RNA in
cells anticipated to be exposed to either stable or transiently ris-
ing serum iron levels. Additionally, at the T 5 0, T 5 4.5, T 5
7, and T 5 24 hours time points, 10 mL of blood was processed
using the designated cEC Enrichment & Enumeration Kit (Mil-
tenyi Biotec, Bergisch Gladbach, Germany), following training
in Bergisch Gladbach, and according to the published protocol.
Further methodological details are provided in the Supporting
Methods in the online version of this article.
Data Analyses
In the 2012 HHT survey, responses to questions about
nosebleeds, telangiectasia, and AVMs permitted the assignment
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of HHT with confidence in 1,080 of the 1,433 survey respond-
ents, using the algorithm in Hosman et al.,48 which is based on
the Curac¸ao Criteria.52 For a further 174 participants, a diagno-
sis of HHT could not be assigned with complete confidence. To
understand and minimize potential bias, data were analyzed
both including (n 5 1,288) and excluding (n 5 1,080) this “likely
HHT” group. Survey statistical analyses were performed using
Stata IC version 12 (StataCorp, College Station, TX) and Prism
version 6.0 (GraphPad Software, San Diego, CA). Categorical
data were compared using v2 analyses; two group comparisons
by Mann-Whitney, and for three or more groups, P values were
calculated using Kruskal-Wallis with Dunn’s post-test correction
applied.
The trial data were analyzed in Stata IC version 12, and
Prism 6. No changes were made to over study numbers, and all
data (six iron/TfSI time points, four circulating endothelial cell
time points) on all 18 participants are reported. Single time
point, two-group comparisons were performed using Mann-
Whitney; three-group comparisons were performed using
Kruskal-Wallis. Multiple time point, two- or three-group com-
parisons were performed using two-way analysis of variance.
Serum ferritin changes were modeled using the 48-hour change
as the dependent variable in linear regression.
RESULTS
HHT Population Demographics
The 2012 survey was completed by 1,467 interna-
tional respondents, with the majority of respondents
residing in the USA. One hundred seventy-nine had no
suggestion of HHT–many had completed the survey as
spouses, friends, or staff members. A total of 1,288 who
stated they had HHT or were blood relatives of an HHT
patient reported nosebleeds, telangiectasia in character-
istic sites, and/or AVMs. Their median age was 55 years,
and 732 (57.3%) were women. Six hundred one (46.6%)
had pulmonary AVMs, 216 (16.8%) hepatic AVMs, 100
(8.5%) gastrointestinal HHT, and 105 (8.1%) cerebral
AVMs, rates comparable to those reported in other HHT
series. Nosebleeds affected 1,262 of 1,288 (98%), includ-
ing 523 (40.6%) at least once daily, a further 405 (31.4%)
weekly, and 183 (14.2%) at least once per.
Of these 1,288 respondents, 837 (65.0%) had used
iron tablets, 273 (21.2%) had received iron infusions,
and 396 (30.8%) had received blood transfusions. One
hundred five of 1,288 (8.1%) had been transfused on at
least 10 different occasions. The majority of the 396
receiving blood transfusions had also received iron tab-
lets (364 of 396, 91.9%). Similarly, 258 of 273 (94.5%)
iron infusion users had received iron tablets, including
220 who answered a question about concurrent usage.
When iron infusions were commenced, more than half of
these respondents had their iron tablets stopped (137 of
220, 62.3%). Smaller proportions continued using iron
tablets (92 of 220, 42%), or described varying patterns of
cessation (13, 5.4%).
Iron Treatments and HHT Nosebleeds
Iron treatments are usually started in adult life,
and at first sight, the iron-using group appeared to have
more nosebleeds earlier in life, or in response to trauma
(see Supporting Fig. 6 in the online version of this arti-
cle). However, the population of 1,288 respondents was
likely to include a small proportion of people without
HHT, who would tend to have fewer nosebleeds, and use
iron less frequently, therefore biasing the data.
Responses to questions about nosebleeds, telangiectasia,
and AVMs permitted the assignment of HHT with com-
plete confidence in 1,080 respondents. When analyses
were restricted to these 1,080 respondents, there was no
difference in the proportion of iron users reporting nose-
bleed during childhood, or following trauma, compared
to nonusers (Fig. 1A), indicating that less rigorous phe-
notyping would have introduced an important bias in
this setting.
In the 1,080 individuals with a confident diagnosis
of HHT, 781 (72.3%) reported current or previous use of
iron tablets, and 261 (24.2%) had received intravenous
iron. Iron tablet users were more likely to have daily
Fig. 1. Nosebleed frequency in study respondents, categorized by iron use. (A) Percentage (%) of the 1,080 respondents in whom heredi-
tary hemorrhagic telangiectasia could be confidently assigned, reporting any nosebleed ever, nosebleeds in childhood, or nosebleeds in
response to trauma or injury. Open circles indicate the 299 patients who had never used iron tablets, diamonds indicate the 781 users of
iron tablets, and filled circles indicate the 359 who had used iron tablets without intravenous iron or blood transfusions. Mean and standard
error are indicated. (B) Percentage (%) of groups reporting no nosebleeds ever (“never”), <5 in lifetime, or nosebleeds at least once per
year, once per month, once per week, or once per day. Symbols are as in A.
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nosebleeds than non–iron-tablet users (Fig. 1B). This
was more pronounced in patients who also required
intravenous iron infusions or blood transfusions (Fig.
1B), and would be expected, because frequent nosebleeds
lead to iron deficiency and the need for additional iron
intake.22
However, of the 732 iron tablet users reporting
nosebleed associations, 35 (4.8%) reported that nose-
bleeds appeared to be worse after iron tablets. Similarly,
of the 261 using intravenous iron, 17 (6.5%) reported
that nosebleeds seemed worse after iron infusions. The
proportion of those reporting nosebleeds that were worse
after oral iron was similar after the subgroup of patients
who also used intravenous iron was excluded (20 of 442,
4.5%).
To evaluate whether these reports may reflect
methodological bias or reporting noise, the proportions
were compared to the proportion of individuals reporting
nosebleed changes in response to control investigations
not expected to modify blood vessels or serum iron (Fig.
2). Only two individuals reported any changes in nose-
bleeds after control investigations (one after a blood test,
one after being weighed). Using blood tests as a compari-
son, the proportion of those reporting nosebleeds who
worsened after iron treatments was significantly higher
for users of iron tablets (v2, P 5 .031), and intravenous
iron (v2, P 5 .0084; Fig. 2).
Reported iron exacerbation of nosebleeds was
restricted to a subgroup of HHT patients. Most iron-
using participants reported no change in nosebleeds
after iron treatments, whereas 56 of 732 (7.6%) using
iron tablets and 34 of 261 (13.0%) using iron infusions
reported nosebleed improvement. One iron tablet user
reported both improvements and exacerbations on differ-
ent occasions. We remained concerned that iron treat-
ments appeared to sometimes augment the hemorrhagic
losses they were required to replace.
Rapid Rises in Serum Iron Levels Following
Ferrous Sulfate (200 mg)
To evaluate whether there could be a plausible link
between oral iron ingestion and acute vascular changes
leading ultimately to an HHT nosebleed, serum iron
indices were evaluated in serial blood samples from the
18 healthy volunteers randomized to receive a single
200-mg ferrous sulfate tablet, a dietary iron supplement,
or no agent (Fig. 3A).
Blinded biochemical assessments demonstrated
sharp rises in serum iron concentrations to supranormal
concentrations in four of the 18 study participants.
When the study was unblinded, all four “absorbers” had
received ferrous sulfate (Fig. 3A). Baseline serum iron
had been comparable in the three groups (median values
5 17.1 lmol/L in controls, 14.6 lmol/L in iron treatment
group, and 12.5 lmol/L in the dietary supplement group,
P 5 0.59 by Kruskal-Wallis).
The sharpest rises in serum iron concentrations
occurred within 2 hours of oral iron ingestion. Compared
to the normal range for serum iron concentrations (7–27
lmol/L), the absolute 2-hour rises in the four iron
absorbers averaged 28.2 lmol/L (range 5 19.3–33.1
lmol/L). The changes in the remaining 14 nonabsorbers
ranged from 22.2 to 5.0 lmol/L (mean 5 0.8 lmol/L;
Fig. 4A).
Serum iron concentrations remained high for sev-
eral hours. Seven hours after ingestion of the iron tablet
(at 17:00 hours), the median values were 30.1 lmol/L
in the iron-treated group compared to 15.6 lmol/L in
controls, and 13.0 lmol/L in the molasses group (P 5
0.015 by Kruskal-Wallis).
Biological Sequelae
The majority of circulating iron is sequestered by
transferrin.23,28,53 The percentage of transferrin binding
sites occupied by iron (TfSI) is used in clinical practice
as an index of iron deficiency and iron overload, with a
normal range of 20% to 40%.23,28,53 The four healthy vol-
unteers demonstrating sharp rises in serum iron also
exhibited sharp rises in TfSI concentrations, again
to values substantially exceeding the normal range
(Fig. 4A).
Participants displaying a higher rise in serum iron
had greater increases in serum ferritin, considered to be
an important marker of iron stores.23,28,53 By linear
regression, for each micromole per liter greater increase
in serum iron at 2 hours, the serum ferritin at 48 hours
Fig. 2. Reported exacerbation of nosebleeds after treatments and
investigations. Percentage (%) of patients reporting that iron tab-
lets, infusions, or blood transfusions exacerbated nosebleeds
compared to a subgroup of 460 reporting responses to the control
investigations in the second survey. N indicates number of
respondents reporting responses for the treatment or investiga-
tion. *P < .05 compared to equivalent responses in control investi-
gations. Note that the iron and transfusion data are from all 1,288
participants with confident and likely hereditary hemorrhagic telan-
giectasia (HHT), as this group was more comparable to the control
survey population, although the proportions reporting exacerba-
tion by iron treatments were marginally lower than in the 1,080
participants with rigorously defined HHT (see text).
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was 0.21 lg/L (95% confidence interval 0.002 to 0.41)
higher (P 5 0.048).
Circulating endothelial cells (cEC) are considered a
marker of endothelial damage, have a normal range of
<20/mL, and are substantially increased in several vas-
cular diseases.54,55 In the 18 healthy volunteers, all cEC
counts were normal at baseline (<20/mL), but rises were
seen in a proportion of the study group. When the study
was unblinded, cEC counts remained normal in all con-
trols and iron-treated nonabsorbers. However, in the
high iron absorbers there were transient rises in cEC
counts (Fig. 4B).
DISCUSSION
Replacement of lost iron is an essential part of the
management of patients with nosebleeds and other hem-
orrhagic iron losses. Current iron treatments have ele-
mental iron contents far in excess of the usual dietary
daily intakes, which rarely reach 20mg/day.22 This study
demonstrates that for approximately 1 in 20 people with
HHT, iron replacement treatments may aggravate nose-
bleeds. The study also provides a plausible link through
biochemical and cellular studies.
The main strengths of the study are the capture of
data from a very large iron-using population who can
report vascular sequelae in real time, and the clinical
trial that provides novel insights into responses to iron
tablet ingestion. The main study weaknesses are that
survey data are subjective, and observational data can-
not demonstrate causality. Additionally, the iron treat-
ment evaluations were performed in a control population
(although this is relevant to wider groups of people
using iron), and involved small study numbers.
The most common side effects from iron tablets are
gastrointestinal, which often limit tolerance; the strong-
est data are from a 1966 trial56 and were recently sum-
marized for easier access.22 The current data, using a
Fig. 3. Iron treatment trial. (A) Study protocol. Black arrows indicate time of blood samples, red arrows indicate the time of administration
of ferrous sulfate (FeSO4) 200 mg, and blue dotted arrows indicate the time of administration of the dietary supplement (Diet supp; molas-
ses). (B) Serum iron concentrations (normal range 5 7–27 lmol/L) in the 18 healthy volunteers before (T 5 0) and after ingestion of ferrous
sulfate (solid lines), molasses (dotted lines), or no agent (dashed lines). Note all four rapid increases were in individuals receiving ferrous
sulfate.
Fig. 4. Biomarkers in iron treatment trial. (A) Change in serum iron (upper graph) and transferrin saturation index (TfSI, lower panel) in the
first 2 hours after iron administration, categorized by absorber groups. Boxplots display interquartile range and 2 standard deviations. Prob-
ability values for iron absorber status were calculated by two-way analysis of variance using T 5 0 and T 5 2 hours data. (B) Circulating
endothelial cells (ECs; viable CD341CD452CD1461 cells) in the iron treatment and control groups, categorized by iron absorption status.
Boxplots display median, interquartile range, and 2 standard deviations; dots at extremes represent outliers. At each of the 4-5 and 7-hour
time points, one of the molasses group also demonstrated circulating EC rises (data not shown).
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population able to report vascular sequelae in real time,
raise the additional challenging issue that for approxi-
mately one in 20 patients with HHT, iron treatments for
anemia may also exacerbate HHT nosebleeds in a
vicious circle. Mechanisms are likely to relate to the
rapid changes in serum iron that can occur, as reported
here and in other studies.36–42 Preliminary evidence is
provided to suggest that the vascular endothelium may
be a potential target. Because iron is recognized to cause
oxidant and other endothelial injury,43–45 further exami-
nation is warranted.
These study findings need to be considered in con-
junction with the substantial risks of untreated iron
deficiency.23–35 Furthermore, for 7% to 13% of HHT
patients, iron treatments were reported to improve nose-
bleeds. We suspect that on these occasions, nosebleeds
had been aggravated by the high cardiac outputs
required to maintain tissue oxygen delivery when
patients were anemic,29,33,57–60 and that improvements
(when cardiac outputs were reduced) offset any possible
precipitant effects due to endothelial injury.
For clinical practice, these data raise questions
about iron tablet dosages, particularly because factors
regulating gastrointestinal iron absorption are better
understood27,28,53,61 than when conventional strength
iron tablets were introduced >50 years ago.56 Single dos-
ages of tablets available over the counter at leading
pharmacies provide 65 mg of elemental iron, compared
to recommended dietary allowances of 8 mg/day, increas-
ing to 18 mg/day for premenopausal females.25 These
allowances are often unmet through dietary intake
alone.22,25,26,62–64 Additionally, hepcidin/ferroportin-
dependent mechanisms mean that iron deficient individ-
uals generally absorb a higher proportion of ingested
iron, and gastrointestinal absorption may be further
enhanced in patients who are actively bleeding,61 or
with cirrhotic liver diseases.65 In contrast, patients with
chronic and/or inflammatory disease states with inap-
propriately elevated hepcidin have more limited gastro-
intestinal iron absorption, irrespective of ingested iron
doses.53,66
CONCLUSION
In conclusion, iron treatments remain essential, but
we suggest there is a rationale to consider reduced
strength iron tablets, closer to the recommended dietary
allowance. More frequent administration of lower indi-
vidual iron dosages may be helpful for individual HHT
patients reporting that their nosebleeds increase after
commencing or escalating iron treatments for anemia.
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